775 related articles for article (PubMed ID: 32991072)
1. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
3. Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Nakayama H; Tabuchi K; Tawa A; Tsukimoto I; Tsuchida M; Morimoto A; Yabe H; Horibe K; Hanada R; Imaizumi M; Hayashi Y; Hamamoto K; Kobayashi R; Kudo K; Shimada A; Miyamura T; Moritake H; Tomizawa D; Taga T; Adachi S
Int J Hematol; 2014 Aug; 100(2):171-9. PubMed ID: 24961644
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
5. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
[TBL] [Abstract][Full Text] [Related]
6. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
[TBL] [Abstract][Full Text] [Related]
7. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
8. Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Moritake H; Tanaka S; Nakayama H; Miyamura T; Iwamoto S; Shimada A; Terui K; Saito A; Shiba N; Hayashi Y; Tomizawa D; Taga T; Goto H; Hasegawa D; Horibe K; Mizutani S; Adachi S
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28233452
[No Abstract] [Full Text] [Related]
9. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
11. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
15. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
17. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
18. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
20. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.
Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Hallböök H
Haematologica; 2012 Sep; 97(9):1414-21. PubMed ID: 22511497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
